Navigation Links
Drug a New Treatment Option for Diabetic Eye Disease
Date:4/28/2010

Lucentis is first new therapy against diabetic macular edema in a quarter-century, experts say

WEDNESDAY, April 28 (HealthDay News) -- A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report.

Lucentis (ranibizumab) was originally developed to treat age-related macular degeneration. But researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.

The study of 691 patients with DME found that 50 percent of those who received Lucentis eye injections, plus laser treatment if necessary, had substantial improvement in vision one year after treatment, compared with 28 percent of patients who received laser treatment alone. Results were similar after two years.

For 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.

The study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.

According to the U.S. National Eye Institute, DME occurs when fluid leaks into the center of the macula, the portion of the eye dedicated to sharp, straight-ahead vision. The condition is common in people with diabetic retinopathy, which affects up to 45 percent of people with diabetes.

The results of the new study "appear to be applicable to most people who have DME in the center of the macula with some vision loss, whether the person has type 1 or type 2 diabetes, is old or young, or is a woman or a man," Dr. Neil M. Bressler, chair of the DRCR Network and chief of the retina division, Wilmer Eye Institute, at Johns Hopkins University School of Medicine, said in a news release.

This is a "seminal" study," added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.

"First and most importantly, it provides patients an improved therapy for diabetic macular edema. Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment," Williams said.

The American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.

More information

The American Diabetes Association has more about diabetes-related eye complications.



-- Robert Preidt



SOURCE: American Academy of Ophthalmology, news release, April 27, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. CBDM.T, The Market and Business Intelligence Company Reviews The Dry Eye Disease Treatment Market
2. Study examines global availability of treatment involving transplantation of blood stem cells
3. Study finds that drugs used for treatment of influenza in pregnancy appear to be safe
4. Comparative-effectiveness study confirms new treatment for diabetic macular edema
5. Allergy Treatment from Absolute Health Provides Allergy Elimination as Opposed to Allergy Prevention
6. CureTogether Announces Online Autism Treatment Study
7. Nonmedical treatment may rapidly relieve severe IBS symptoms
8. New Varicose Vein Treatment Center Opens in Prescott, Arizona
9. Non-medical treatment may rapidly relieve severe IBS symptoms
10. Immune cells predict success of head and neck cancer treatment, U-M study finds
11. New report confirms fears of people living with HIV: Treatment rationing escalating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen Miller ... to communities in the greater Birmingham area, is joining the Chris Hammond Youth ... people in the region. , The Chris Hammond Youth Foundation maintains athletic facilities ...
(Date:7/21/2017)... ... ... Fresh Wave® IAQ today announced the launch of its innovative Smoke ... the APPA 2017 Annual Conference and Exhibition in Booth #414. , Specifically ... use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid is ...
(Date:7/21/2017)... , ... July 21, 2017 , ... Hospital M&A activity ... HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the second quarter, ... and up 15% from the 20 announced deals in the year-ago second quarter. Only ...
(Date:7/21/2017)... ... ... The Margarian Law Firm has filed a class action lawsuit against ... no ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In ... Ginger Ale claims on its bottle that it is made from real ginger. , ...
(Date:7/21/2017)... Basking Ridge, NJ (PRWEB) , ... July 21, ... ... Hills (VNA) has received a $5,000 grant from the C. R. ... Adult Day Center at Somerset Hills , a service available through the ...
Breaking Medicine News(10 mins):
(Date:7/19/2017)... RALEIGH, N.C. , July 19, 2017  Mako ... Veteran Affairs, and the Military Family Assistance Fund (MFA) ... Louisiana to visit with their families one ... the funding to coordinate the travel and logistics needed ... supporting our deployed soldiers and their families. We just ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful carpal tunnel ... syndrome affects more than 8 million people a year. Women suffer ... common methods of treating CTS are painful surgery, the use of ... ... is a clear patch worn on the palm of the hand. ...
Breaking Medicine Technology: